Literature DB >> 30654213

Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy.

Tong-Fei Li1, Yong-Hong Xu2, Ke Li3, Chao Wang1, Xin Liu1, Yuan Yue1, Zhuo Chen1, Shen-Jun Yuan1, Yu Wen1, Quan Zhang1, Min Han4, Naoki Komatsu5, Li Zhao6, Xiao Chen7.   

Abstract

Immunosuppression is a salient feature of GBM associated with the disease's grim prognosis and the limited success of anti-GBM immunotherapy. Stimulating immunogenicity of the GBM cells (GC) is a promising approach to subverting the GBM-associated immunosuppression. We had previously devised a drug composite based on polyglycerol-functionalized nanodiamonds bearing doxorubicin (Nano-DOX) and demonstrated that Nano-DOX effectively modulated GBM's immunosuppressive microenvironment through stimulating the immunogenicity of GC and initiated anti-GBM immune responses. The present study now explored the mechanism of Nano-DOX's immunostimulatory action. Nano-DOX was found to induce autophagy rather than apoptosis in GC and stimulated GC to emit antigens and damage-associated molecular patterns (DAMPs) that are potent adjuvants, which resulted in enhanced activation of dendritic cells (DC). Heightened autophagosome release was observed in Nano-DOX-treated GC but was shown not to be a major channel of antigen donation. Blocking autophagy in GC not only reduced Nano-DOX-stimulated GC antigen donation and DAMPs emission, but also efficiently attenuated DC activation stimulated by Nano-DOX-treated GC. Taken together, these findings suggest that activation of autophagy is a central mechanism whereby Nano-DOX stimulates GC's immunogenicity. Our work provides new insight on how nanotechnology can be applied to therapeutically modulate the GBM immune microenvironment by harnessing autophagy in the cancer cells. STATEMENT OF SIGNIFICANCE: Immunosuppression is a salient feature of GBM associated with the grim prognosis of the disease and the limited success of anti-GBM immunotherapy. We demonstrated that Doxorubicin-polyglycerol-nanodiamond composites could activate autophagy in GBM cells and thereby stimulate the immunogenecity of GBM cells. This discovery 1, sheds new light on how nanotechnology could be applied to therapeutically modulate the tumor immune microenvironment, and 2, provides a powerful tool for subverting the GBM's immunosuppressive microenvironment, which has great therapeutic potential for the treatment of GBM.
Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autophagy; Doxorubicin; Glioblastoma; Immunogenicity; Nanodiamond

Mesh:

Substances:

Year:  2019        PMID: 30654213     DOI: 10.1016/j.actbio.2019.01.020

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  16 in total

Review 1.  Regulation of autophagy as a therapeutic option in glioblastoma.

Authors:  Amanda J Manea; Swapan K Ray
Journal:  Apoptosis       Date:  2021-10-23       Impact factor: 4.677

2.  Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.

Authors:  Mohammad Norouzi; Vinith Yathindranath; James A Thliveris; Brian M Kopec; Teruna J Siahaan; Donald W Miller
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

Review 3.  Emerging nanomedicines for effective breast cancer immunotherapy.

Authors:  Amirhossein Bahreyni; Yasir Mohamud; Honglin Luo
Journal:  J Nanobiotechnology       Date:  2020-12-09       Impact factor: 10.435

Review 4.  Calreticulin-Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients.

Authors:  Michal Kielbik; Izabela Szulc-Kielbik; Magdalena Klink
Journal:  Cells       Date:  2021-01-11       Impact factor: 6.600

Review 5.  The functions of autophagy at the tumour-immune interface.

Authors:  Xiaobo Luo; Yan Qiu; Palani Dinesh; Wang Gong; Lu Jiang; Xiaodong Feng; Jing Li; Yuchen Jiang; Yu L Lei; Qianming Chen
Journal:  J Cell Mol Med       Date:  2021-02-18       Impact factor: 5.310

Review 6.  Breaking Bad: Autophagy Tweaks the Interplay Between Glioma and the Tumor Immune Microenvironment.

Authors:  Yuxiang Fan; Yubo Wang; Jian Zhang; Xuechao Dong; Pu Gao; Kai Liu; Chengyuan Ma; Gang Zhao
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

7.  Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.

Authors:  Hua-Zhen Xu; Tong-Fei Li; Chao Wang; Yan Ma; Yan Liu; Mei-Yan Zheng; Zhang-Jun-Yan Liu; Jin-Bo Chen; Ke Li; Shi-Kuan Sun; Naoki Komatsu; Yong-Hong Xu; Li Zhao; Xiao Chen
Journal:  J Nanobiotechnology       Date:  2021-09-06       Impact factor: 10.435

Review 8.  Nanoscale Drug Delivery Systems in Glioblastoma.

Authors:  Zihao Liu; Xiaoshuai Ji; Dong He; Rui Zhang; Qian Liu; Tao Xin
Journal:  Nanoscale Res Lett       Date:  2022-02-16       Impact factor: 5.418

Review 9.  Nanotechnology-aided advancement in the combating of cancer metastasis.

Authors:  Leela Rani Avula; Piotr Grodzinski
Journal:  Cancer Metastasis Rev       Date:  2022-04-02       Impact factor: 9.237

10.  Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.

Authors:  Shen-Jun Yuan; Yong-Hong Xu; Chao Wang; Hui-Chao An; Hua-Zhen Xu; Ke Li; Naoki Komatsu; Li Zhao; Xiao Chen
Journal:  J Nanobiotechnology       Date:  2019-10-17       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.